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Abstract 
Background: Rhabdomyolysis is frequently occurring in critically ill patients, resulting in a high risk of acute kidney 
injury (AKI) and potentially permanent kidney damage due to increased myoglobin levels. The extracorporeal elimina-
tion of myoglobin might be an approach to prevent AKI, but its molecular weight of 17 kDa complicates an elimina-
tion with conventional dialysis membranes. Question of interest is, if myoglobin can be successfully eliminated with 
the cytokine adsorber Cytosorb® (CS) integrated in a high-flux dialysis system.
Methods: Patients were included between 10/2014 and 05/2020 in the study population if they had an anuric renal 
failure with the need of renal replacement therapy, if CS therapy was longer than 90 min and if myoglobin level 
was > 5.000 ng/ml before treatment. The measurement times of the laboratory values were: d-1 = 24–36 h before CS, 
d0 = shortly before starting CS and d1 = 12–24 h after starting CS treatment. Statistical analysis were performed with 
Spearman’s correlation coefficient, Wilcoxon test with associated samples and linear regression analysis.
Results: Forty-three patients were included in the evaluation (median age: 56 years, 77% male patients, 32.6% ECMO 
therapy, median SAPS II: 80 points and in-hospital mortality: 67%). There was a significant equilateral correlation 
between creatine kinase (CK) and myoglobin at all measurement points. Furthermore, there was a significant reduc-
tion of myoglobin (p = 0.03, 95% confidence interval (CI): − 9030, − 908 ng/ml) during CS treatment, with a median 
relative reduction of 29%. A higher median reduction of 38% was seen in patients without ongoing rhabdomyolysis 
(CK decreased during CS treatment, n = 21). In contrast, myoglobin levels did not relevantly change in patients with 
increasing CK and therefore ongoing rhabdomyolysis (n = 22, median relative reduction 4%). Moreover, there was no 
significant difference in myoglobin elimination in patients with and without ECMO therapy.
Conclusion: Blood purification with Cytosorb® during high-flux dialysis led to a significant reduction of myoglobin 
in patients with severe rhabdomyolysis. The effect might be obscured by sustained rhabdomyolysis, which was seen 
in patients with rising CK during treatment. Prospective clinical trials would be useful in investigating its benefits in 
avoiding permanent kidney damage.
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Introduction
Rhabdomyolysis describes the disintegration of skeletal 
muscles, leading to the release of muscle components 
into the blood [1]. The most common cause is trau-
matic damage of the muscles, for example in patients 
after multiple traumas [2]. However, the clinical picture 
can also occur as part of severe sepsis and due to drug 
side effects [3]. Ultimately, many intensive care unit 
(ICU) patients are affected. In addition to electrolyte 
disorders caused by cell decay, there is also an accu-
mulation of creatine kinase (CK) and myoglobin in the 
blood [4]. Even though there are no uniform diagnostic 
criteria, rhabdomyolysis is typically referred to when 
the CK is > 5 times the upper normal [5].
After muscle damage, CK reaches its maximum value 
in the blood after about 24 h and is then inactivated by 
oxidation in the blood independently of liver and kid-
ney function [6]. Persistent muscle damage can further 
increase serum CK levels. Myoglobin reaches its maxi-
mum value in the blood within about 12 h after muscle 
damage and is rapidly eliminated by the kidneys. The 
half-life is about 3 h, if kidney function is unrestricted 
and muscle damage is not persistent [7]. However, an 
accumulation of large amounts of myoglobin might 
have nephrotoxic effects although a clear mechanism 
about the renal toxicity is still not clear. Thus, renal 
vasoconstriction, the formation of intratubular casts 
and direct toxic effect of myoglobin on the tubule cells 
might lead to acute kidney injury (AKI) and the clinical 
picture of the “crush kidney” [8].
A frequently used conservative treatment option in 
preventing AKI is the alkalization of the urine, but no 
randomized controlled study showed its benefits so far. 
However, renal replacement therapy (RRT) is necessary 
in many ICU patients due to ongoing AKI [9]. Although 
the amount of CK defines rhabdomyolysis, its elimina-
tion is of secondary importance due to the absence of 
toxicity [10]. In contrast, myoglobin can cause persis-
tent and potentially permanent damage of the tubular 
epithelial cells in the kidney and its elimination from 
the blood might be an approach to avoid AKI [8]. The 
problem is that myoglobin, with a molecular weight 
of approximately 17  kDa, is only poorly removed by 
many standard dialysis membrane used in critically ill 
patients with the need of RRT [8, 11]. The surface area 
of the dialyzers is often between 1 and 2  m2 and the 
sieving coefficient for myoglobin mostly between 0.2 
and 0.4.
One solution for a better myoglobin removal is the 
use of high cut-off (HCO) dialyzers. Heyne et  al. [12] 
described this approach in a case series with an effective 
removal of myoglobin. Furthermore, Weidhase et  al. 
[13] recently published the results of a randomized 
trial, where a higher myoglobin clearance can be seen 
in patients treated with HCO dialyzers in contrast 
to the typically used high-flux dialyzers. Both had the 
same surface area of 1.8  m2 and myoglobin clearance 
was about 8–10 ml/min for HCO dialyzers and 2–3 ml/
min for high-flux dialyzers. Another method is plasma-
pheresis, where a successful myoglobin elimination had 
also been described [14]. A new approach is the use of 
the cytokine adsorbed Cytosorb® (CS) (CytoSorbents 
Europe, Berlin, Germany), which is primarily intended 
for the elimination of cytokines in hyperinflammatory 
conditions [15]. It has a surface area of about 45.000 
 m2 and hydrophobic molecules up to a size of approxi-
mately 55  kDa can be eliminated. The product has a 
CE mark for the elimination of myoglobin since 2019. 
Based on its molecular weight of 80 kDa, an elimination 
of CK cannot be assumed.
Although in vitro data showed the elimination of myo-
globin by CS [16], there is a lack of clinical studies in the 
literature, except of two case reports. [17, 18]. Due to the 
lack of data describing the effects of CS in patients with 
rhabdomyolysis, a retrospective data analysis was investi-
gated in critically ill patients with severe rhabdomyolysis 
and CS therapy. Within the scope of clinical practice, CS 
was used at two anesthesiological ICUs at the LMU hos-
pital in Munich in patients with severe rhabdomyolysis 
and the need of RRT. To evaluate the clinical experience 
in a structured way and to gain first results on the in-vivo 
efficacy of CS in critically ill patients with rhabdomyoly-
sis, a retrospective data analysis was performed.
Methods
Study setting
This was a single-center, retrospective observational 
study investigating the effects of CS therapy in critically 
ill patients with AKI and rhabdomyolysis. Patients were 
included between October 2014 and May 2020 during 
their stay at two ICUs at the LMU hospital in Munich. 
The local institutional review board approved the study 
(registration number 20-477).
Laboratory measurements and data collection
All clinical–chemical parameters were determined with 
standard clinical chemistry tests in the institute of labo-
ratory medicine. CK was measured using a kinetic test, 
so all different isoforms are included. Myoglobin was 
measured with a muscular specific immunoassay. Demo-
graphic data, clinical variables and laboratory variables 
were collected from the laboratory and patient informa-
tion system. Baseline characteristics (age, gender, body 
mass index (BMI), extracorporeal membrane oxygena-
tion (ECMO), days at ICU till treatment with CS, 7-days 
mortality, in-hospital mortality, sequential organ failure 
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assessment (SOFA) score, Simplified Acute Physiology 
Score (SAPS) II, reason for admission to ICU and reason 
for rhabdomyolysis) were evaluated on the treatment day. 
Laboratory data (CK, myoglobin and lactate serum levels) 
were collected daily before and during the intervention.
Study population
All patients, who were treated with CS between 10/2014 
and 05/2020, were screened for evaluation. Patients were 
only included in the study population when CS therapy 
was longer than 90  min and it was the first treatment 
interval. Furthermore, myoglobin serum level had to 
be over 5000  ng/ml, measured directly before CS treat-
ment. Furthermore, a myoglobin level had to be meas-
ured directly after CS therapy. A repetitive application 
took place partially, but was excluded in our evaluation. 
Moreover, only patients with anuria and the need of con-
tinuous RRT with high-flux dialysis (Fresenius Ultraflux® 
AV 600S, surface area 1.4  m2, myoglobin sieving coeffi-
cient ~ 0.3) were included.
Blood sampling
In the data evaluation, three time points were considered 
depending on CS treatment:
• d-1: 24–36 h before starting CS therapy.
• d0: 0–12  h before starting CS therapy (= directly 
before treatment).
• d1: 12–24 h after starting CS therapy (= end of treat-
ment or immediately after the end).
Statistical analysis
Statistical analysis was performed with IBM SPSS statis-
tics (Version 26.0. IBM Corp., Armonk, NY, USA). The 
effect of CS treatment on the reduction of myoglobin in 
relation to CK was investigated. Continuous variables are 
given as median and interquartile range (IQR) or with 
minimum and maximum. The relative change of the 
parameters (%) was calculated with: 100 − ((100/param-
eter d0) * parameter d1). As laboratory variables had no 
normal distribution in the Shapiro–Wilk test, nonpara-
metric tests were used. Spearman’s correlation coefficient 
was used for correlation analysis and Wilcoxon test with 
associated samples was used to describe the change of 
CK and myoglobin before and during CS treatment. To 
identify confounders on the effect of myoglobin elimi-
nation with CS (relative change of myoglobin during 
CS therapy), a linear regression analysis was performed. 
Independent variables were: relative change of CK (%) 
(d0–d1), CK d0, myoglobin d0, lactate d0, relative change 
of lactate (%) (d0–d1), SAPS II d0 and ECMO therapy. To 
identify baseline changes and changes in the elimination 
of myoglobin in patients with and without ECMO-ther-
apy, the U-test was used.
Results
Demographic and clinical data
In total, 43 patients were included in the evaluation. CS 
was integrated into a continuous renal replacement pro-
cedure as all patients had an AKI requiring RRT. The 
main diagnoses at admission to the ICU were as follows, 
in descending order: acute respiratory distress syndrome 
(ARDS) (30.2%), polytrauma (18.6%), septic shock (14.0%) 
and solid organ transplantation (14.0%). The reason for 
rhabdomyolysis was as follows, in descending order: 
infection/septic shock (41.9%), trauma (23.2%), hypov-
olemic or cardiogenic shock (14.0%), metformin intoxica-
tion (2.3%) and unknown origin (18.6%). The median age 
was 56 years, 77% were male and 32.6% needed support 
with ECMO therapy. All patients were critically ill, which 
was reflected in a median SAPS II of 80 points, which 
predicted a mortality rate of 92.5%. The actual in-hospital 
mortality rate was 67.4%. Detailed patient characteristics 
can be found in Table 1.
Comparison of CK and myoglobin levels before and after 
Cytosorb® treatment
The laboratory parameters were examined at d-1, d0 and 
d1 as described in the method section. Furthermore, the 
relative change (%) during the time periods (d-1/d0) and 
(d0/d1) for both CK and myoglobin was analyzed. Spear-
man’s correlation coefficient showed a significant, mod-
erate equilateral correlation in the comparison of CK and 
myoglobin at all time points.
Statistical analysis with the Wilcoxon test with asso-
ciated samples showed a significant increase of CK in 
the period prior to CS treatment (p < 0.001, CI 2287, 
5923 U/l) with a median relative change of + 129.2% 
(IQR: 45.8%, 310.1%). It was the same for myoglobin 
prior to CS therapy (p < 0.001, CI 8774, 20,173  ng/ml) 
with a median relative change of + 106.1% (IQR: 40.6%, 
213.1%). There was no significant change of CK during 
CS therapy (p = 0.419, CI − 1542, 669 U/l; median rela-
tive change + 1.0% (IQR: − 28.3, + 78.2%)). In contrast, 
a significant reduction of myoglobin can be seen during 
CS treatment (p = 0.03, CI − 9030, − 908  ng/ml) with a 
median relative change of − 29.4% (IQR: − 41.2, + 2.6%). 
Figure 1 shows the course of CK and myoglobin prior and 
during CS therapy as box plots.
A regression analysis was performed to detect deter-
minants that affect the change of myoglobin during CS 
therapy. The only significant factor that influenced the 
relative change of myoglobin was the relative change of 
CK during the same period (p < 0.001, CI 0.39, 0.61). All 
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other parameters had no significant impact on the rela-
tive change of myoglobin during CS treatment.
Effect of Cytosorb® in different groups
We assumed that myoglobin elimination by CS therapy 
was not visible in laboratory measurement due to per-
sistent rhabdomyolysis with accumulation of further 
myoglobin and CK. Therefore, patients were divided 
into two groups depending on whether CK increased or 
decreased during CS application. Group 1 (n = 21) was 
defined as patients with decreasing CK during CS and 
group 2 (n = 22) was defined as patients with increas-
ing CK, which is equal to an ongoing muscle injury. 
Figure 2 shows the relative change (= 100 − ((100/param-
eter d0) * parameter d1) of myoglobin und CK during CS 
treatment. Patients allocated to group 1 are presented as 
green dots and patients allocated to group 2 as red dots.
The periods prior to CS (d-1/d0) and the period during 
CS (d0/d1) were analyzed concerning CK and myoglo-
bin levels and relative change in the two different groups. 
Detailed results can be found in Table 2.
There was a significant increase of CK (p = 0.025, CI 
1495, 19,168 U/l) and myoglobin (p = 0.01, CI 6749, 
37442  ng/ml) in patients allocated to group 1 prior to 
CS treatment. Moreover, a significant decrease of both 
CK (p < 0.001, CI − 3777, − 1168 U/l) and myoglobin 
(p < 0.001, − 19,386, − 7111  ng/ml) can be seen. The 
median relative reduction of myoglobin was 38%.
In contrast, there was no significant change, neither for 
CK (p = 0.201, CI − 2478, 8898 U/l), nor for myoglobin 
(p = 0.147, CI − 6472, 19,502  ng/ml) prior to CS treat-
ment in patients allocated to group 2. During treatment 
with CS, a significant increase in CK (p < 0.001, CI 1861, 
6946 U/l) was observed in those patients, while there was 
no significant change of myoglobin (p = 0.858, CI − 4954, 
29,770 ng/ml).
Figure  3 shows the median CK and myoglobin levels 
in the different groups. The course of CK and myoglobin 
was equal in the observed period in patients allocated to 
group 1. It was the same in patients allocated to group 
2 prior to CS therapy with increasing CK and myoglo-
bin levels. In contrast, CK serum levels increased rap-
idly during CS treatment, while myoglobin serum levels 
remained nearly unchanged.
Myoglobin elimination in patients with and without ECMO 
therapy
In total, 14 patients needed support with ECMO therapy 
and had therefore a high risk for hemolysis. The median 
LDH (U/l) at d0 in patients with and without ECMO ther-
apy was 1566 (IQR: 767, 3824) and 825 (IQR: 690, 3190) 
with no significant difference in the U-test (p = 0.50). 
Furthermore, there was no difference in median myo-
globin d0 (ng/ml) with 26,760 (IQR: 17,318, 35,311) and 
25,012 (12,587, 37,562) in patients with and without 
ECMO-therapy (p = 0.88), respectively. The median rela-
tive reduction during CS treatment was 26.2% in ECMO-
patients and 34.4% in patients without ECMO-therapy. A 
significant difference was also here not to be recognized 
(p = 0.31).
Discussion
To the best of the authors’ knowledge, this is the first 
analysis of the effectiveness of the cytokine adsorber 
Cytosorb® integrated into a continuous high-flux dialy-
sis system for myoglobin elimination in critically ill 
patients with severe rhabdomyolysis, apart from case 
reports. With 43 patients, the study represents the larg-
est population in which blood purification was used for 
myoglobin elimination. A SAPS II of 80 points was indic-
ative for the severity of disease of the study population. 
A median myoglobin level of > 25,000  ng/ml before the 
start of CS therapy underlines the massive rhabdomyoly-
sis. Although all conservative therapeutic options should 
be exhausted to avoid a crush kidney [9, 19], acute renal 
failure can usually not be avoided, especially at such high 
myoglobin concentrations.
Since extracorporeal myoglobin elimination is only 
insufficiently possible with high-flux dialysis (small 
Table 1 Patient characteristics and  laboratory 
measurements
BMI body mass index, ECMO extracorporeal membrane oxygenation, ICU 
intensive care unit, SOFA sequential organ failure assessment, SAPS Simplified 
Acute Physiology Score, CK creatine kinase, d day
n (%) or median 
[Range: min, max]
Patient characteristics
 Age (years) 56 [18, 84]
 Gender: male/female 33 (76.7)/10 (23.3)
 BMI (kg/m2) 26.7 [15.2, 45.0]
 ECMO therapy 14 (32.6)
 Days at ICU till treatment 2 [0, 30]
 7-day mortality 11 (25.6)
 In-hospital mortality 29 (67.4)
 SOFA score on treatment day 19 [8, 23]
 SAPS II on treatment day 80 [40, 115]
Laboratory measurements
 Myoglobin d-1 (ng/ml) 9938 [1253, 260,000]
 Myoglobin d0 (ng/ml) 25,281 [7033, 252,000]
 Myoglobin d1 (ng/ml) 22,871 [3548, 163,000]
 CK d-1 (U/l) 2389 [96, 33,643]
 CK d0 (U/l) 6752 [855, 200,000]
 CK d1 (U/l) 6652 [822, 90,350]
Page 5 of 9Scharf et al. Crit Care           (2021) 25:41  
surface area and low sieving coefficient), several special 
elimination procedures are available. As all patients had 
an anuric renal failure, the authors do not assume a rel-
evant endogenous myoglobin elimination in the study 
population. The median myoglobin clearance of a simi-
lar high-flux filter was recently described by Weidhase 
et al. [13] with approximately 2–3 ml/min. However, a 
new alternative for myoglobin elimination might be CS, 
whose integration into an, for example, existing high-
flux dialysis system is quick and easy. Even though there 
is regular approval for the usage of CS in patients with 
rhabdomyolysis in the European Union, there is a gen-
eral lack of clinical studies [16]. It is important to know 
which molecules can theoretically be eliminated by CS 
based on their molecular size. The cutoff value of CS 
based on manufacturer’s specifications is about 55 kDa. 
Therefore, the elimination of myoglobin with a molecu-
lar size of 17  kDa is possible [20], whereas CK with a 
size of about 80  kDa cannot be eliminated [21]. With 
this assumption, the elimination of CK by CS described 
by Dilken et  al. [18] must be critically questioned and 
is most likely based on the endogenous decay and not 
on removal by CS. This was also clearly stated by Daum 
et al. [22], who referred directly to the case report pre-
sented by Dilken et al.
A median relative reduction rate of 29% is a great suc-
cess, especially with persistent rhabdomyolysis. Ongoing 
rhabdomyolysis might be the reason, why the effect of CS 
is often difficult to detect in laboratory measurements. 
However, correlation analysis revealed that there was a 
significant correlation between the CK and myoglobin 
values, and regression analysis showed that the change in 
CK during CS was the only factor that influenced myo-
globin levels. Therefore, the two variables seem compa-
rable, even though the flooding time and half-life of the 
substances are different [23].
Due to organ-independent degradation, there should be 
a relevant reduction of CK during CS application, assum-
ing an expired rhabdomyolysis. In contrast, if the CK 
continues to increase, there might be an ongoing rhab-
domyolysis. Therefore, two groups were formed based on 
this assumption. In conclusion, a significant reduction of 
myoglobin (median relative reduction: 38%) was detected 
in patients with decreasing CK (group 1). Since all 
patients had an anuric renal failure, renal elimination of 
myoglobin cannot be assumed and, in the authors’ view, 
the reduction of myoglobin was largely due to the use of 
CS and not due to the high-flux dialyzer. The elimination 
rate was comparable to a study in pigs, where a myoglo-
bin elimination of 41% by CS was described [24]. How-
ever, it should be noted that degradation pathways with 
spleen and liver have been rarely described [25].
Although no significant change in myoglobin was 
observed in patients with increasing CK (group 2), the 
Fig. 1 CK and myoglobin values of all patients at different time points. Myo Myoglobin, CK creatine kinase, d-1 24–36 h before Cytosorb® treatment, 
d0 0–12 h before CS treatment, d1 12–24 h after beginning Cytosorb® treatment, orange line represents the median, gray boxes the interquartile 
range and the whiskers are limited to 1.5 times the interquartile range
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elimination was evident from the substantial increase 
of CK during CS application (median relative increase 
of 78%), while there was a median decrease of 4% for 
myoglobin. Without CS therapy, a rapid increase in 
myoglobin, equivalent to the previously unidirectional 
change in CK and myoglobin, would be expected in those 
Fig. 2 Relative change (%) of myoglobin and CK during CS treatment. CK creatine kinase, CS Cytosorb®, green dots: decrease of CK during CS 
treatment (= group 1), red dots: increase of CK during CS treatment (= group 2)
Table 2 CK and myoglobin in the two different groups
CK creatine kinase, Myo myoglobin
CK Median (IQR) or relative change 
[IQR]
Myoglobin Median (IQR) 
or relative change 
[IQR]
Group 1 (decreasing CK)
 CK d-1 2715 (887, 6392) Myoglobin d-1 16,417 (6474, 25,622)
 CK d0 6982 (4605, 9903) Myoglobin d0 29,514 (20,744, 38,317)
 CK d1 4962 (2802, 7946) Myoglobin d1 19,355 (10,481, 29,667)
 100 − ((100/CK d-1) * CK d0) 132% [29, 513] 100 − ((100/Myo d-1) * Myo d0) 73% [37, 132]
 100 − ((100/CK d0) * CK d1) − 28% [− 39, − 19] 100 − ((100/Myo d0) * Myo d1) − 38% [− 53, − 18]
Group 2 (increasing CK)
 CK d-1 1833 (776, 4011) Myoglobin d-1 9406 (5081, 10,701)
 CK d0 4178 (2232, 11,731) Myoglobin d0 23,264 (12,956, 27,769)
 CK d1 11,819 (5112, 20,193) Myoglobin d1 24,297 (14,044, 53,745)
 100 − ((100/CK d-1) * CK d0) 126% [79, 283] 100 − ((100/Myo d-1) * Myo d0) 166% [97, 351]
 100 − ((100/CK d0) * CK d1) 78% [21, 126] 100 − ((100/Myo d0) * Myo d1) − 4% [− 30, 69]
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patients as well. Although the absence of an increase did 
not prove that CS therapy was successful, this must be 
supposed from the authors’ perspective.
As one-third of our patients needed support with 
ECMO-therapy, which potentially influences the perfor-
mance of CS, a subgroup analysis was performed. Neither 
a more pronounced hemolysis, nor higher myoglobin 
levels before treatment or a significant difference in the 
relative myoglobin reduction can be seen. Although our 
population is not generally applicable to all other ICU 
patients, we conclude that ECMO therapy might not 
have relevant impact on CS elimination performance.
No clinical studies that examine the evidence of CS in 
the context of rhabdomyolysis are available. It further 
remains unclear whether and how much myoglobin elim-
ination leads to less kidney damage and faster comple-
tion of dialysis. In this context, our study can provide the 
foundation for future prospective projects. Overall, other 
blood purification systems can also be used for the elimi-
nation of myoglobin [12, 26–29]. The advantages of CS 
compared to, for example, plasmaphereses are that albu-
min, with a molecular size of 66–67 kDa, is not absorbed 
and that it can be easily and temporarily integrated into 
an existing dialysis system. Ultimately, all procedures lack 
both individual studies and comparative studies ques-
tioning the clinical relevance of myoglobin elimination. 
Therefore, a final evaluation according to the best proce-
dure is not possible.
In summary, myoglobin removal with the cytokine 
adsorber CS integrated into a high-flux dialyzer can be 
recommended for clinical routine due to its existing CE 
mark, ease of use and absence of side effects. Even though 
an advantage in patient outcome has not yet been con-
firmed, extracorporeal elimination seems to be useful 
especially in cases of high myoglobin levels and existing 
AKI. Therefore, potentially permanent damage of the 
renal tubules cells caused by the accumulation of myo-
globin could be prevented [30]. Nevertheless, prospective 
studies are lacking in which the myoglobin clearance of 
CS can be accurately determined by a dense blood col-
lection scheme and, for example, simultaneous meas-
urements at the adorber’s in—and outlet, to determine 
cross-adsorber clearance.
Fig. 3 Median CK and myoglobin levels in the different groups. CK creatine kinase, Myo myoglobin, − 1: day − 1, 0: day 0, 1: day 1, green beams: 
decrease of CK during CS treatment (= group 1), red beams: increase of CK during CS treatment (= group 2)
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Finally, this study has several limitations. First, it was 
a retrospective, single-center data analysis, whereby 
laboratory parameters were collected in clinical routine. 
Although the time of blood collection and the duration 
of treatment with CS were electronically documented, a 
slight deviation was still possible. Second, there was no 
control group, so the course of myoglobin without CS 
could not be assessed and elimination outside the kidneys 
may have played a minor role. In this context, a statement 
on the difference in patients’ outcome with and without 
CS treatment is not possible. Third, CK was measured 
using a kinetic test, so the CK value included all isoforms. 
Last, statements about the myoglobin clearance and satu-
ration kinetics of the CS absorber are not possible due to 
the relatively sparse blood sampling scheme. Moreover, 
small amounts of myoglobin can also be eliminated by 
the high-flux dialysis and the elimination was therefore a 
combination of CS therapy and high-flux dialysis.
Conclusion
Blood purification with Cytosorb® integrated into a high-
flux dialyzer may be a useful tool for the elimination of 
myoglobin in critically ill patients with rhabdomyoly-
sis. Myoglobin elimination could avert permanent kid-
ney damage by avoiding its deposition in the kidney. A 
measurable effect might be obscured during sustained 
rhabdomyolysis, seen in patients with a rising CK during 
treatment. Thus, in-vivo pre- and post-adsorber meas-
urements would be useful for investigating the elimina-
tion rate and elimination kinetic of myoglobin during CS 
treatment. Prospective randomized trials would, further-
more, be useful to examine the clinical benefits in terms 
of recovery of kidney function and patient outcome.
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